RECORD // Company

Cero Therapeutics Holdings, Inc.

Formerly: CERO THERAPEUTICS HOLDINGS, INC.; PHOENIX BIOTECH ACQUISITION CORP.

Built 2026-11-22T03:56:23Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • CERo Therapeutics Holdings, Inc. · Ctgov · same registered legal name as 'CERO THERAPEUTICS HOLDINGS, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • CERO THERAPEUTICS HOLDINGS INC · Epa echo · same registered legal name as 'CERO THERAPEUTICS HOLDINGS, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001213900-26-119677

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$4,019,1123 months ended 2026-09-3010-Q2026-11-130001213900-26-1196772026-11-22 03:56 UTCReport an error
Interest expense$917,6693 months ended 2026-09-3010-Q2026-11-130001213900-26-1196772026-11-22 03:56 UTCReport an error
Cash and cash equivalents$455,925at 2026-09-3010-Q2026-11-130001213900-26-1196772026-11-22 03:56 UTCReport an error

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001870404
Ticker
CERO
EIN
871088814
Record ID
sx:sec:0001870404

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

22 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-13SEC EDGAR company profile2026-11-22 03:56 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-13SEC EDGAR company profile2026-11-22 03:56 UTCReport an error
State of incorporationDE2026-11-13SEC EDGAR company profile2026-11-22 03:56 UTCReport an error
Fiscal year end (MMDD)12312026-11-13SEC EDGAR company profile2026-11-22 03:56 UTCReport an error
Business address201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 940802026-11-13SEC EDGAR company profile2026-11-22 03:56 UTCReport an error
ExchangesOTC, OTC2026-11-13SEC EDGAR company profile2026-11-22 03:56 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-19,920,2622025-12-3110-K, XBRL NetIncomeLoss2026-11-22 03:56 UTCReport an error
Total assets (at 2025-12-31)$3,641,1342025-12-3110-K, XBRL Assets2026-11-22 03:56 UTCReport an error
Stockholders' equity (at 2025-12-31)$-5,446,4622025-12-3110-K, XBRL StockholdersEquity2026-11-22 03:56 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$1,662,3802025-12-3110-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents2026-11-22 03:56 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-16,100,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 03:56 UTCReport an error
Operating lease liabilities (at 2025-12-31)$699,1072025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 03:56 UTCReport an error
Form D total offering amount (D filed 2025-05-06)$8,000,0002025-05-06D2026-11-22 03:56 UTCReport an error
Form D total amount sold (D filed 2025-05-06)$5,000,0002025-05-06D2026-11-22 03:56 UTCReport an error
Form D industry groupPharmaceuticals2025-05-06D2026-11-22 03:56 UTCReport an error
Form D revenue rangeNo Revenues2025-05-06D2026-11-22 03:56 UTCReport an error
Form D date of first sale2025-04-222025-05-06D2026-11-22 03:56 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-07)Stock Purchase Agreement On October 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company” or “Holdings”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with SRX Global Inc., a Delaware corporation formerly known as SRX Health Solutions, Inc. (“SRX” or the “Buyer”). Subject to the terms and conditions of the Purchase Agreement, Holdings will sell to the Buyer all of the outstanding capital stock of CERo Therapeutics, Inc., its wholly owned operating subsidiary (the “Subsidiary”), which sale is referred to herein as the “Transaction.” Upon completion of the Transaction (the “Closing”), Holdings will cease to own the Subsidiary. In connection…2026-10-07SEC EDGAR 8-K 0001213900-26-107410 (text as filed, excerpt)2026-11-22 03:56 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive (filed 2026-08-31)Agreement. On August 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), completed a secured financing transaction with SRX Global Inc. (formerly known as SRx Health Solutions, Inc.) (“SRX”). In connection with the transaction, the Company issued to SRX a Consolidated Senior Secured Promissory Note having an original issue date of August 27, 2026 (the “Note”). Prior to the transaction, SRX was a lender to the Company under certain of the promissory notes described below. The Note consolidates certain outstanding convertible grid promissory notes previously issued by the Company (collectively, the “Previous Notes”), including (i) obligations under Previous…2026-08-31SEC EDGAR 8-K 0001213900-26-095776 (text as filed, excerpt)2026-11-22 03:56 UTCReport an error
8-K Item 1.02, Termination of a Material Definitive (filed 2026-08-31)Agreement. The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.02. In connection with the issuance of the Note, the Previous Notes, including their conversion and other terms, were superseded and replaced in their entirety by the Note. The unpaid principal and accrued interest under the Previous Notes were consolidated into the original principal amount of the Note rather than repaid at the time of the transaction.2026-08-31SEC EDGAR 8-K 0001213900-26-095776 (text as filed, excerpt)2026-11-22 03:56 UTCReport an error
8-K Item 2.03, Creation of a Direct Financial Obligation (filed 2026-08-31)or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03. 22026-08-31SEC EDGAR 8-K 0001213900-26-095776 (text as filed, excerpt)2026-11-22 03:56 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-08-31)The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The issuance of the Note was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act, for the offer and sale of securities not involving a public offering. The Company’s reliance upon Section 4(a)(2) of the Securities Act in issuing the Note was based upon the following factors: (a) the issuance of the Note was an isolated private transaction by us which did not involve a public offering; (b) the Lender is an accredited investor; (c) the Company did not engage in general solicitation or advertising in connection with the issuance; and (d)…2026-08-31SEC EDGAR 8-K 0001213900-26-095776 (text as filed, excerpt)2026-11-22 03:56 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.